Evaluation of potential immunogenicity differences between Pandemrix™ and Arepanrix™

References

• Mereckiene J, Cotter S, Weber JT, Nicoll A, D'Ancona F, Lopalco PL, Johansen K, Wasley AM, Jorgensen P, Lévy-Bruhl D, et al. Influenza A(H1N1)pdm09 vaccination policies and coverage in Europe. Euro Surveill 2012; 17(4):pii=20064; PMID:22297139; http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20064
   PubMedGoogle Scholar
• Ahmed SS, Schur PH, MacDonald NE, Steinman L. Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants. J Autoimmun 2014; 50:1-11; PMID:24559657; http://dx.doi.org/10.1016/j.jaut.2014.01.033
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Narcolepsy in association with pandemic influenza vaccination - a multi-country European epidemiological investigation). Stockholm: ECDC; September 2012. Accessed 10-03-2015. http://www.ecdc.europa.eu/en/publications/publications/vaesco%20report%20final%20with%20cover.pdf
   Google Scholar
• Wijnans L, Lecomte C, de Vries C, Weibel D, Sammon C, Hviid A, Svanström H, Mølgaard-Nielsen D, Heijbel H, Dahlström LA, et al. The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine 2013; 31:1246-54; PMID:23246544; http://dx.doi.org/10.1016/j.vaccine.2012.12.015
   PubMed Web of Science ®Google Scholar
• Kornum B, Faraco J, Mignot E. Narcolepsy with hypocretin/orexin deficiency, infections and autoimmunity of the brain. Curr Opin Neurobiol 2011; 21:897-903; PMID:21963829; http://dx.doi.org/10.1016/j.conb.2011.09.003
   PubMed Web of Science ®Google Scholar
• van der Most R, Van Mechelen M, Destexhe E, Wettendorff M, Hanon E. Narcolepsy and A(H1N1)pdm09 vaccination: Shaping the research on the observed signal. Hum Vaccin Immunother 2014; 10:572-6; PMID:24342916; http://dx.doi.org/10.4161/hv.27412
   PubMed Web of Science ®Google Scholar
• Montplaisir J, Petit D, Quinn MJ, Ouakki M, Deceuninck G, Desautels A, Mignot E, De Wals P. Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec. PLoS One 2014; 9:e108489; PMID:25264897; http://dx.doi.org/10.1371/journal.pone.0108489
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Association of receipt of Pandemrix™ and narcolepsy in children and adolescents in the UK (England). Accessed 18-03-2013. http://ecdc.europa.eu/en/activities/sciadvice/_layouts/forms/Review_DispForm.aspx?List=a3216f4c-f040-4f51-9f77-a96046dbfd72&ID=735
   Google Scholar
• Jacob L, Leib R, Ollila HM, Bonvalet M, Adams CM, Mignot E. Comparison of Pandemrix and Arepanrix, two pH1N1 AS03-adjuvanted vaccines differentially associated with narcolepsy development. Brain Behav Immun 2014; S0889-1591(14):00519-4
   Google Scholar
• Vaarala O, Vuorela A, Partinen M, Baumann M, Freitag TL, Meri S, Saavalainen P, Jauhiainen M, Soliymani R, Kirjavainen T, et al. Antigenic differences between AS03 adjuvanted influenza A (H1N1) pandemic vaccines: implications for Pandemrix-associated narcolepsy risk. PLoS One 2014; 9:e114361; PMID:25501681; http://dx.doi.org/10.1371/journal.pone.0114361
   PubMed Web of Science ®Google Scholar
• Ahmed SS, Volkmuth W, Duca J, Corti L, Pallaoro M, Pezzicoli A, Karle A, Rigat F, Rappuoli R, Narasimhan V, et al. Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2. Sci Transl Med 2015; 7:294ra105; PMID:26136476; http://dx.doi.org/10.1126/scitranslmed.aab2354
   PubMed Web of Science ®Google Scholar
• Launay O, Duval X, Fitoussi S, Jilg W, Kerdpanich A, Montellano M, Schwarz TF, Watanveerade V, Wenzel JJ, Zalcman G, et al. Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials. BMC Infect Dis 2013; 13:435; PMID:24041010; http://dx.doi.org/10.1186/1471-2334-13-435
   PubMed Web of Science ®Google Scholar
• Langley JM, Frenette L, Ferguson L, Riff D, Sheldon E, Risi G, Johnson C, Li P, Kenney R, Innis B, et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J Infect Dis 2010; 201:1644-53; PMID:20423222; http://dx.doi.org/10.1086/652701
   PubMed Web of Science ®Google Scholar
• Steward MW. The biological significance of antibody affinity. Immunol Today 1981; 2:134-40; PMID:25289455; http://dx.doi.org/10.1016/0167-5699(81)90079-7
   PubMedGoogle Scholar
• Usinger WR, Lucas AH. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect Immun 1999; 67:2366-70; PMID:10225896
   PubMed Web of Science ®Google Scholar
• Khurana S, Wu J, Dimitrova M, King LR, Manischewitz J, Graham BS, Ledgerwood JE, Golding H. DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults. J Infect Dis 2013; 208:413-7; PMID:23633404; http://dx.doi.org/10.1093/infdis/jit178
   PubMed Web of Science ®Google Scholar
• Junker AK, Tilley P. Varicella-zoster virus antibody avidity and IgG-subclass patterns in children with recurrent chickenpox. J Med Virol 1994; 43:119-24; PMID:8083659; http://dx.doi.org/10.1002/jmv.1890430204
   PubMed Web of Science ®Google Scholar
• Breukels MA, Jol-van der Zijde E, van Tol MJ, Rijkers GT. Concentration and avidity of anti-Haemophilus influenzae type b (Hib) antibodies in serum samples obtained from patients for whom Hib vaccination failed. Clin Infect Dis 2002; 34:191-7; PMID:11740707; http://dx.doi.org/10.1086/338259
   PubMed Web of Science ®Google Scholar
• Pedersen GK, Höschler K, Øie Solbak SM, Bredholt G, Pathirana RD, Afsar A, Breakwell L, Nøstbakken JK, Raae AJ, Brokstad KA, et al. Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination. Vaccine 2014; 32:4550-7; PMID:24950357; http://dx.doi.org/10.1016/j.vaccine.2014.06.009
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Kalinke U, Althage A, Freer G, Burkhart C, Roost H, Aguet M, Hengartner H, Zinkernagel RM. The role of antibody concentration and avidity in antiviral protection. Science 1997; 276:2024-7; PMID:9197261; http://dx.doi.org/10.1126/science.276.5321.2024
   PubMed Web of Science ®Google Scholar
• Olotu A, Clement F, Jongert E, Vekemans J, Njuguna P, Ndungu FM, Marsh K, Leroux-Roels G, Bejon P. Avidity of anti-circumsporozoite antibodies following vaccination with RTS,S/AS01E in young children. PLoS One 2014; 9:e115126; PMID:25506706; http://dx.doi.org/10.1371/journal.pone.0115126
   PubMed Web of Science ®Google Scholar
• Monsalvo AC, Batalle JP, Lopez MF, Krause JC, Klemenc J, Hernandez JZ, Maskin B, Bugna J, Rubinstein C, Aguilar L, et al. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat Med 2011; 17:195-9; PMID:21131958; http://dx.doi.org/10.1038/nm.2262
   PubMed Web of Science ®Google Scholar
• To KK, Zhang AJ, Hung IF, Xu T, Ip WC, Wong RT, Ng JC, Chan JF, Chan KH, Yuen KY. High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza. Clin Vaccine Immunol 2012; 19:1012-8; PMID:22573737; http://dx.doi.org/10.1128/CVI.00081-12
   PubMed Web of Science ®Google Scholar
• Khurana S, Verma N, Yewdell JW, Hilbert AK, Castellino F, Lattanzi M, Del Giudice G, Rappuoli R, Golding H. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med 2011; 3:85ra48; PMID:21632986; http://dx.doi.org/10.1126/scitranslmed.3002336
   PubMed Web of Science ®Google Scholar
• Khurana S, Verma N, Talaat KR, Karron RA, Golding H. Immune response following H1N1pdm09 vaccination: differences in antibody repertoire and avidity in young adults and elderly populations stratified by age and gender. J Infect Dis 2012; 205:610-20; PMID:22207649; http://dx.doi.org/10.1093/infdis/jir791
   PubMed Web of Science ®Google Scholar
• Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, Rock MT, Edwards KM, Del Giudice G, Rappuoli R, et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med 2010; 2:15ra5; PMID:20371470; http://dx.doi.org/10.1126/scitranslmed.3000624
   PubMed Web of Science ®Google Scholar
• Lynch HE, Stewart SM, Kepler TB, Sempowski GD, Alam SM. Surface plasmon resonance measurements of plasma antibody avidity during primary and secondary responses to anthrax protective antigen. J Immunol Methods 2014; 404:1-12; PMID:24316020; http://dx.doi.org/10.1016/j.jim.2013.11.026
   PubMed Web of Science ®Google Scholar
• Dauner JG, Pan Y, Hildesheim A, Kemp TJ, Porras C, Pinto LA. Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals. Mol Cell Probes 2012; 26:73-80; PMID:22285687; http://dx.doi.org/10.1016/j.mcp.2012.01.002
   PubMed Web of Science ®Google Scholar
• Hearty S, Conroy PJ, Ayyar BV, Byrne B, O'Kennedy R. Surface plasmon resonance for vaccine design and efficacy studies: recent applications and future trends. Expert Rev Vaccines 2010; 9:645-64; PMID:20518719; http://dx.doi.org/10.1586/erv.10.52
   PubMed Web of Science ®Google Scholar
• Harris T, Wong K, Stanford L, Fediurek J, Crowcroft N, Deeks S. Did narcolepsy occur following administration of AS03-adjuvanted A(H1N1) pandemic vaccine in Ontario, Canada? A review of post-marketing safety surveillance data. Euro Surveill 2014; 19(36):pii=20900; PMID:25232921; http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20900
   PubMedGoogle Scholar
• Stiehm ER, Fudenberg HH. Serum levels of immune globulins in health and disease: a survey. Pediatrics 1966; 37:715-27; PMID:4956666
   PubMed Web of Science ®Google Scholar
• Katsamba PS, Navratilova I, Calderon-Cacia M, Fan L, Thornton K, Zhu M, Vanden Bos T, Forte C, Friend D, Laird-Offringa I, et al. Kinetic analysis of a high-affinity antibody/antigen interaction performed by multiple Biacore users. Anal Biochem 2006; 352:208-21; PMID:16564019; http://dx.doi.org/10.1016/j.ab.2006.01.034
   PubMed Web of Science ®Google Scholar
• García-Ojeda PA, Hardy S, Kozlowski S, Stein KE, Feavers IM. Surface plasmon resonance analysis of antipolysaccharide antibody specificity: responses to meningococcal group C conjugate vaccines and bacteria. Infect Immun 2004; 72:3451-60; PMID:Can't; http://dx.doi.org/10.1128/IAI.72.6.3451-3460.2004
   PubMedGoogle Scholar
• Gibbs E, Karim ME, Oger J. Antibody dissociation rates are predictive of neutralizing antibody (NAb) course: A comparison of interferon beta-1b-treated Multiple Sclerosis (MS) patients with transient versus sustained NAbs. Clin Immunol 2014; 157:91-101; PMID:25543089; http://dx.doi.org/10.1016/j.clim.2014.12.005
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. European Public Assessment Report (EPAR) for Pandemrix, EMA/691037/2013. Annex I: Summary of product characteristics Accessed 13-03-2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000832/human_med_000965.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Leroux-Roels I, Borkowski A, Vanwolleghem T, Drame M, Clement F, Hons E, Devaster JM, Leroux-Roels G. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370:580-9; PMID:17707753; http://dx.doi.org/10.1016/S0140-6736(07)61297-5
   PubMed Web of Science ®Google Scholar
• Stenberg E, Persson B, Roos H, Urbaniczky C. Quantitative determination of surface concentration of protein with surface plasmon resonance using radiolabeled proteins. J Colloid Interface Sci 1991; 143:513-26; http://dx.doi.org/10.1016/0021-9797(91)90284-F
   Web of Science ®Google Scholar